Upon KCTD15 silencing, an increment of the chemotherapeutic effect of doxorubicin, a generic chemotherapy drug, and of Trastuzumab, an innovative monoclonal antibody widely used in HER2+ BC, was observed. Here, KCTD15 is linked to breast cancer.